LifeMD is trading 7.8% down now at $2.26, with broad market weakness the likeliest explanation.
- Major indices are sharply lower amid concerns about AI regulation and technology-sector selling; market context also describes a sharp November 5 sell-off.
- LifeMD announced an arrangement allowing its pharmacy to dispense and ship Lilly self-pay GLP-1 medicines, but the announcement does not explain the decline.